Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,318,201

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,318,201 protect, and when does it expire?

Patent 8,318,201 protects NOURIANZ and is included in one NDA.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 8,318,201
Title:Method of stabilizing diarylvinylene compound
Abstract: ##STR00001## (wherein Y.sup.1 and Y.sup.2 may be the same or different and each represents a hydrogen atom, halogen or lower alkyl; and Z and A may be the same or different and each represents substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl) The present invention provides, for example, a method for stabilization of a diarylvinylene compound such as a compound represented by the above formula (I) or the like, or a pharmaceutically acceptable salt thereof in a solid formulation containing the diarylvinylene compound or the pharmaceutically acceptable salt thereof, which comprises allowing an inorganic substance and/or a colorant to exist in the solid formulation, and the like.
Inventor(s): Uchida; Akihiro (Sunto-gun, JP), Ishikawa; Yasuhiro (Sunto-gun, JP), Ueno; Yasuhiko (Mishima, JP), Kaji; Kiichiro (Machida, JP), Aimoto; Masaharu (Sunto-gun, JP), Kaneko; Naoki (Sunto-gun, JP)
Assignee: Kyowa Hakko Kirin Co., Ltd. (Tokyo, JP)
Application Number:10/528,451
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,318,201

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,318,201

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-336944Sep 29, 2003
PCT Information
PCT FiledSeptember 29, 2004PCT Application Number:PCT/JP2004/014687
PCT Publication Date:April 07, 2005PCT Publication Number: WO2005/030219

International Family Members for US Patent 8,318,201

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 046169 ⤷  Free Forever Trial
Australia 2004275646 ⤷  Free Forever Trial
Canada 2540109 ⤷  Free Forever Trial
China 1845742 ⤷  Free Forever Trial
European Patent Office 1676578 ⤷  Free Forever Trial
Spain 2534220 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.